Literature DB >> 32513793

In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination.

Karin Meinike Jørgensen1, Karen M T Astvad1, Maiken Cavling Arendrup2,3,4.   

Abstract

Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001), currently in clinical development for the treatment of invasive fungal infections. We compared manogepix EUCAST minimum effective concentrations (MECs) to MICs of five comparators and CLSI MECs and MICs by a colorimetric method against contemporary molds. EUCAST susceptibility testing was performed for 161 isolates. Interlaboratory and intermethod reproducibility were determined by comparison with published manogepix MECs. Colorimetric MICs (measuring metabolic activity) were evaluated using three Aspergillus fumigatus isolates and one Aspergillus flavus isolate with four inocula at 24 to 48 h of incubation and 1 to 3 h 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT)/menadione (MEN) exposure. Manogepix modal MECs (range in mg/liter) against Aspergillus species were 0.03 to 0.06 (0.008 to 0.125) and unaffected by itraconazole resistance. Manogepix was as active against two Fusarium isolates but inactive against Trichophyton interdigitale, Lichtheimia ramosa, and Rhizomucor pusillus isolates (MECs >0.5). Modal MEC/MICs were ≥3 2-fold dilutions apart without overlapping ranges comparing manogepix with amphotericin B, isavuconazole, and voriconazole against Aspergillus isolates. Manogepix and posaconazole MECs/MICs correlated for Aspergillus niger (Pearson's r = 0.711; P = 0.0044). The MEC at which 50% of the isolates tested are inhibited (MEC50), mode, and MEC90 values were within ±1 dilution in all cases compared with published EUCAST and CLSI data. The colorimetric method showed excellent agreement with the MECs when plates were inoculated with the lowest inoculum (1 × 102 CFU/ml to 2.5 × 102 CFU/ml), incubated for 24 h, and exposed for 1 to 3 h to XTT/MEN. Broad-spectrum in vitro activity of manogepix against clinically relevant molds was confirmed with excellent agreement across EUCAST and CLSI methods reported from experienced mycology laboratories. Colorimetric MIC determination warrants further investigation as a potential alternative that is less dependent on mycology expertise.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  APX001; APX001A; Aspergillus; CLSI; EUCAST; antifungal susceptibility testing; fosmanogepix; manogepix; mold

Mesh:

Substances:

Year:  2020        PMID: 32513793      PMCID: PMC7526828          DOI: 10.1128/AAC.00730-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi.

Authors:  Conrad L Schoch; Keith A Seifert; Sabine Huhndorf; Vincent Robert; John L Spouge; C André Levesque; Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-27       Impact factor: 11.205

2.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William Hope
Journal:  Clin Microbiol Infect       Date:  2012-05-08       Impact factor: 8.067

3.  In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies.

Authors:  Olga Rivero-Menendez; Manuel Cuenca-Estrella; Ana Alastruey-Izquierdo
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

4.  APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis.

Authors:  Miao Zhao; Alexander J Lepak; Karen Marchillo; Jamie Vanhecker; Hiram Sanchez; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.

Authors:  Mariana Castanheira; Frederick P Duncanson; Daniel J Diekema; Josep Guarro; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

7.  Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.

Authors:  Maiken Cavling Arendrup; Susanne Perkhofer; Susan J Howard; Guillermo Garcia-Effron; Aimanianda Vishukumar; David Perlin; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

8.  Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes.

Authors:  N L Glass; G C Donaldson
Journal:  Appl Environ Microbiol       Date:  1995-04       Impact factor: 4.792

9.  In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris.

Authors:  Christopher L Hager; Emily L Larkin; Lisa Long; Fatima Zohra Abidi; Karen J Shaw; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

10.  Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species.

Authors:  Mili Kapoor; Molly Moloney; Quinlyn A Soltow; Chris M Pillar; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

View more
  7 in total

1.  Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs.

Authors:  Maiken Cavling Arendrup; Anuradha Chowdhary; Karin Meinike Jørgensen; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

3.  In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections.

Authors:  Tsidiso G Maphanga; Ruth S Mpembe; Serisha D Naicker; Nelesh P Govender
Journal:  Microbiol Spectr       Date:  2022-02-23

Review 4.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 5.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

6.  In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus.

Authors:  Shareef K Shaheen; Praveen R Juvvadi; John Allen; E Keats Shwab; D Christopher Cole; Yohannes G Asfaw; Mili Kapoor; Karen Joy Shaw; William J Steinbach
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.191

Review 7.  Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections.

Authors:  Karen Joy Shaw; Ashraf S Ibrahim
Journal:  J Fungi (Basel)       Date:  2020-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.